株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシー研究ツール・サービス・診断の世界市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

発行 BCC Research 商品コード 350412
出版日 ページ情報 英文 261 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
リキッドバイオプシー研究ツール・サービス・診断の世界市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日: 2019年03月08日 ページ情報: 英文 261 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のリキッドバイオプシー (液体生検) 市場は、2018年の24億米ドルから、2023年までに61億米ドルまで拡大すると見られています。市場は、2018年~2023年のCAGR (複合年間成長率) で、20.8%の成長が予測されています。

当レポートでは、世界のリキッドバイオプシー研究ツール・サービス・診断市場について調査分析し、市場概要、技術の背景、市場動向分析と予測、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • イントロダクション
  • 調査範囲
  • リキッドバイオプシー vs. 従来型バイオプシー
  • 市場
  • 成長促進要因
  • 主要動向
  • 産業

第4章 技術の背景

  • リキッドバイオプシーバイオマーカー
  • 癌ゲノミクス
  • 非侵襲出生前検診
  • 循環腫瘍細胞 (CTC) 技術
  • CTCワークフロー
  • 細胞単離技術
  • CTCサンプル調製技術
  • CTCダウンストリーム分析技術
  • リキッドバイオプシーと従来型バイオプシーとの比較
  • 癌検査
  • 出生前検診

第5章 リキッドバイオプシーイニシアチブ

第6章 市場内訳:エンドユーザー別

  • イントロダクション
  • 癌応用
  • リプロダクティブヘルス応用
  • 移植診断応用

第7章 リキッドバイオプシー産業

  • 先進シークエンシング装置産業
  • ドロップレットデジタルPCR (DDPCR) 産業
  • ターゲットエンリッチメント・調整産業
  • 単細胞DNAポリメラーゼ産業
  • 非侵襲出生前検診産業
  • 胎児細胞NIPT産業
  • CTC採取・検出産業
  • リキッドバイオプシーアッセイ産業

第8章 産業買収と戦略的アライアンス

  • 買収
  • 戦略的アライアンス

第9章 リキッドバイオプシー市場

  • 成長促進要因
  • リキッドバイオプシー市場:適応別
  • リキッドバイオプシー市場:バイオマーカータイプ別
  • リキッドバイオプシー市場:解析プラットフォーム別
  • リキッドバイオプシー市場:解析目的別
  • 非侵襲出生前検診市場
  • 癌市場
  • 移植市場
  • 地域別市場

第10章 特許分析/新規開発

  • CTC特許
  • エキソソーム特許
  • 無細胞DNA特許
  • リキッドバイオプシー・シークエンシング関連特許の問題点

第11章 企業プロファイル

BCC Researchについて

図表

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy Report Scope
    • Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2023
    • Table 4: Forces Driving Growth
    • Table 5: Key Trends in Liquid Biopsy Market
    • Table 6: Liquid Biopsy Industry Subsectors
    • Table 7: Liquid Biopsy Biomarker Classes
    • Table 8: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 9: Genomics-based Oncology Workflow
    • Table 10: Unique Challenges of CTC Capture and Analysis
    • Table 11: CTC Workflow
    • Table 12: Cell Differentiators
    • Table 13: Cell Isolation Technologies
    • Table 14: CTC Sample Preparation Technologies
    • Table 15: Single-Cell Analysis Technologies
    • Table 16: Estimated Annual Solid Biopsy Procedures Performed in the United States for Selected Cancers
    • Table 17: Main Risks for Needle-based Tissue Biopsies
    • Table 18: Factors in Tissue Biopsy
    • Table 19: Prenatal Invasive Testing Technologies
    • Table 20: Invasive Versus Non-invasive Prenatal Technologies
    • Table 21: Key Liquid Biopsy Research and Development Programs
    • Table 22: Single-Cell Core Research Facilities
    • Table 23: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 24: Personalized Medicine Driven by Common Cancer Genetic Mutations
    • Table 25: Cancer Liquid Biopsy Biomarker Clinical Status
    • Table 26: Cancer Liquid Biopsy Market Segments
    • Table 27: Reproductive Health Screening Applications
    • Table 28: Ethical Issues Associated with NIPT
    • Table 29: Transplant Diagnostics Applications
    • Table 30: Key Segments and Trends within the Liquid Biopsy Industry
    • Table 31: Advanced Sequencing Industry Company Positioning
    • Table 32: End-to-End Sequencing Approaches
    • Table 33: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 34: Digital PCR Liquid Biopsy Industry
    • Table 35: Target Enrichment Industry
    • Table 36: Single-Cell DNA Polymerase Industry
    • Table 37: NIPT Industry
    • Table 38: Estimated Market Share for NIPT, 2018
    • Table 39: Germany NGS-based Non-invasive Prenatal Diagnostic Companies, 2017
    • Table 40: NIPT Test Licensing, by Country
    • Table 41: Fetal Cell NIPT Industry
    • Table 42: CTC Separations Industry
    • Table 43: Liquid Biopsy Assay Industry: Company Focus
    • Table 44: Example of NGS-based Liquid Biopsy Market Differentiation
    • Table 45: Liquid Biopsy Industry Acquisitions, January 2017-November 2018
    • Table 46: Liquid Biopsy Strategic Alliances, January 2017-November 2018
    • Table 47: Liquid Biopsy Key Forces Driving Growth and Implications, 2023
    • Table 48: Global Liquid Biopsy Market, by Indication, Through 2023
    • Table 49: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
    • Table 50: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 51: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
    • Table 52: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
    • Table 53: Global NIPT Market, by Analysis Purpose, Through 2023
    • Table 54: Global NIPT Market, by Risk Type, Through 2023
    • Table 55: Global NIPT Market, by Biomarker Class, Through 2023
    • Table 56: Global NIPT Market, by Analysis Method, Through 2023
    • Table 57: Limitations of Solid Biopsy in Cancer Applications
    • Table 58: Low-Frequency Mutation Detection
    • Table 59: Global Liquid Biopsy Cancer Market, by Indication, Through 2023
    • Table 60: Five-year Survival Rate for Ovarian Cancer
    • Table 61: National Institutes of Health Liquid Biopsy Early Detection Initiative
    • Table 62: Molecular Thyroid Nodule Classifier Test Company Positioning
    • Table 63: Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023
    • Table 64: MRI and Liquid Biopsy Methods
    • Table 65: Early Detection Tissue of Origin Approaches
    • Table 66: Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023
    • Table 67: Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023
    • Table 68: Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 69: Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 70: Hematological Cancer Market, by Analysis Method, Through 2023
    • Table 71: Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 72: Global Pan-cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 73: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
    • Table 74: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
    • Table 75: Transplant Procedures Performed in the United States, 2016 to 30 Sept. 2018
    • Table 76: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
    • Table 77: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
    • Table 78: Global Liquid Biopsy Market, by Region, Through 2023
    • Table 79: Global Cancer Liquid Biopsy Market, by Region, Through 2023
    • Table 80: Global NIPT Liquid Biopsy Market, by Region, Through 2023
    • Table 81: Global Transplant Liquid Biopsy Market, by Region, Through 2023
    • Table 82: Patent Activity for Circulating Tumor Cells (CTCs), by Country/Region, 2008-2018
    • Table 83: Patent Activity for Exosomes, by Country/Region, 2008-2018
    • Table 84: Patent Activity for Cell-free DNA (cfDNA), by Country/Region, 2008-2018
    • Table 85: Status of Liquid Biopsy and Sequencing-related Patent Disputes

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
    • Figure 1: How Cancer Genomics Drives Liquid Biopsy
目次
Product Code: BIO150C

Report Highlights:

The global liquid biopsy market should reach $6.1 billion by 2023 from $2.4 billion in 2018 at a compound annual growth rate (CAGR) of 20.8% for the period 2018 to 2023.

The global noncancer liquid biopsy market is expected to grow from $1.9 billion in 2018 to $3.7 billion in 2023 at a CAGR of 13.8% for the period 2018 to 2023.

The global cancer liquid biopsy market is expected to grow from $411.7 million in 2018 to $2.4 billion in 2023 at a CAGR of 41.7% for the period 2018 to 2023.

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents, and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments; droplet digital PCR (polymerase chain reaction); target enrichment; single-cell DNA polymerase; non-invasive prenatal testing (NIPT); fetal-cell NIPT; CTC (circulating tumor cell) capture and detection; and liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics, and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring), and geography (North America, Europe, Asia/Pacific, Rest of World).

Market data covers 2017, 2018 and 2023 (forecasted).

More than 175 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.

Report Includes:

  • 32 data tables and 54 additional tables
  • Industry analysis of the liquid biopsy biomarkers and technologies market
  • Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
  • Discussion of several significant large-scale research initiatives that are contributing to liquid biopsy market development
  • Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
  • Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
  • Company profiles of major manufacturers and suppliers of liquid biopsy research tools, services and diagnostics, including Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, Qiagen, Quantum Biosystems, Roche and Thermo Fisher Scientific

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary

Chapter 3: Overview

  • Introduction

Report Scope

  • Liquid Biopsy Versus Traditional Biopsy
  • Markets
  • Forces Driving Growth
  • Key Trends
  • Industry

Chapter 4: Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Non-Invasive Prenatal Testing
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Prenatal Testing

Chapter 5: Liquid Biopsy Initiatives

  • Blood Profiling Atlas
  • Cancer-ID
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
    • Cambridge Single-Cell Analysis Core Facility
    • Harvard Medical School Single-Cell Core
    • Mayo Medical Genome Facility
    • National Center for Single-Cell Biology
    • Single-Cell Analysis Core
    • UC San Francisco Single-Cell Analysis Center

Chapter 6: Market Breakdown by End User

  • Introduction
  • Cancer Applications
    • Precision Medicine
    • Cancer Biomarker Status
    • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostics Applications

Chapter 7: Liquid Biopsy Industry

  • Advanced Sequencing Instruments Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-Cell DNA Polymerase Industry
  • Non-Invasive Prenatal Testing Industry
  • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry

Chapter 8: Industry Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances
    • Key Trends
    • 2017 Alliances
    • 2018 Alliances

Chapter 9: Liquid Biopsy Markets

  • Forces Driving Growth
  • Liquid Biopsy Market by Indication
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Non-Invasive Prenatal Testing Market
  • Cancer Markets
    • Cancer Market by Indication
    • Cancer Market by Analysis Purpose
    • Cancer Market by Biomarker Class
    • Cancer Market by Analysis Method
    • Breast Cancer Market
    • Colorectal Cancer Market
    • Hematological Cancer Market
    • Lung Cancer Market
    • Pan-cancer Market
  • Transplant Markets
  • Regional Market Analysis

Chapter 10: Patent Review/ New Developments

  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA Patents
  • Liquid Biopsy and Sequencing-related Patent Issues

Chapter 11: Company Profiles

  • ACCURAGEN, INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • ALCEDIAG
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARCEDI BIOTECH APS
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • ATRECA INC.
  • AVIVA BIOSCIENCES
  • BAYLOR GENETICS
  • BECTON, DICKINSON AND CO.
  • BELLWETHER BIO INC.
  • BERRY GENOMICS CO. LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIOCORE CO. LTD.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOMARX INC.
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE LTD.
  • BIOVENDOR-LABORATORNI MEDICINA A.S.
  • BLUESTAR GENOMICS INC.
  • BOREAL GENOMICS
  • CANCER GENETICS INC.
  • CAREDX INC.
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CIRCULOMICS INC.
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • COLOR GENOMICS
  • CS GENETICS LTD.
  • CYGNUS BIOSCIENCES CO. LTD.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOTRACK APS
  • DATAR CANCER GENETICS LTD.
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIRECT GENOMICS CO. LTD.
  • DNA ELECTRONICS LTD.
  • DNALYTICS
  • DNANEXUS INC.
  • DOVETAIL GENOMICS LLC
  • ENVISION GENOMICS
  • EPIC SCIENCES INC.
  • EUROFINS SCIENTIFIC
  • EXACT SCIENCES CORP.
  • EXOSOME SCIENCES INC.
  • EXPEDEON AG
  • EZLIFE BIO INC.
  • FABRIC GENOMICS
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENEDX INC.
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETICS RESEARCH LLC
  • GENOMATIX GMBH
  • GENOMIC HEALTH INC.
  • GENOMONCOLOGY
  • GENOSPACE
  • GENEXOSOME TECHNOLOGIES INC.
  • GIGAGEN INC.
  • GOLDEN HELIX
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HELITEC
  • HELIX OPCO LLC
  • HTG MOLECULAR DIAGNOSTICS INC.
  • ILLUMINA INC.
  • IMMUNOVIA AB
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • KONINKLIJKE PHILIPS N.V.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • MAMMOTH BIOSCIENCES INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME LABS PVT. LTD.
  • MEDOMICS LLC
  • MENARINI SILICON BIOSYSTEMS SPA
  • MERCK KGAA
  • MOLECULAR HEALTH GMBH
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NANOVIEW BIOSCIENCES INC.
  • NATERA INC.
  • NAVERIS INC.
  • NEOGENOMICS LABORATORIES
  • NEW ENGLAND BIOLABS
  • NEW ONCOLOGY GMBH
  • NIPD GENETICS
  • N-OF-ONE INC.
  • NOVOGENE CO. LTD.
  • NUGEN TECHNOLOGIES INC.
  • NUPROBE INC.
  • NX PRENATAL INC.
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PANGAEA ONCOLOGY
  • PARADIGM DIAGNOSTICS INC.
  • PARSEQ LAB CO. LTD.
  • PATHWAY GENOMICS CORP.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PIERIANDX
  • PORTABLE GENOMICS LLC
  • PRECIPIO INC.
  • PREDICINE INC.
  • PREMAITHA HEALTH PLC
  • PRENETICS
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RARECYTE INC.
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SCREENCELL
  • SEEKIN
  • SENGENICS LTD.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLERA GENOMICS INC.
  • SOPHIA GENETICS
  • SPERA MEDICAL
  • SPHERE FLUIDICS LTD.
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT. LTD.
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYSMEX INOSTICS GMBH
  • TAI DIAGNOSTICS INC.
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TRANSPLANT GENOMICS
  • TROVAGENE INC.
  • TWINSTRAND BIOSCIENCES
  • TWO PORE GUYS INC.
  • TYMORA ANALYTICAL OPERATIONS LLC
  • UBIQUITY GENOMICS INC.
  • VORTEX BIOSCIENCES
  • XING TECHNOLOGIES LLC
  • VELA DIAGNOSTICS
  • VOLITIONRX
  • VORTEX BIOSCIENCES
  • YIKON GENOMICS CO. LTD.